Syntara Past Earnings Performance
Past criteria checks 0/6
Syntara ha aumentado sus ingresos a un ritmo medio anual de 30.5%, mientras que la industria Pharmaceuticals ha visto aumentar sus ingresos growing a 31.2% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 3.2%.
Key information
24.9%
Earnings growth rate
33.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 3.8% |
| Return on equity | -170.6% |
| Net Margin | -55.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14
We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04
Revenue & Expenses BreakdownBeta
How Syntara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -11 | 16 | 0 |
| 30 Sep 23 | 12 | -18 | 16 | 0 |
| 30 Jun 23 | 19 | -11 | 16 | 0 |
| 31 Mar 23 | 18 | 2 | 15 | 0 |
| 31 Dec 22 | 8 | -2 | 12 | 0 |
| 30 Sep 22 | 18 | 2 | 15 | 0 |
| 30 Jun 22 | 16 | -2 | 15 | 0 |
| 31 Mar 22 | 14 | -16 | 15 | 0 |
| 31 Dec 21 | 19 | -12 | 15 | 0 |
| 30 Sep 21 | 28 | -1 | 16 | 0 |
| 30 Jun 21 | 24 | -3 | 16 | 0 |
| 31 Mar 21 | 27 | 5 | 16 | 6 |
| 31 Dec 20 | 22 | -4 | 16 | -2 |
| 30 Sep 20 | 12 | -13 | 16 | 6 |
| 30 Jun 20 | 13 | -14 | 16 | 0 |
| 31 Mar 20 | 13 | -21 | 17 | 7 |
| 31 Dec 19 | 13 | -18 | 17 | 7 |
| 30 Sep 19 | 13 | -18 | 16 | 7 |
| 30 Jun 19 | 12 | -20 | 17 | 9 |
| 31 Mar 19 | 7 | -27 | 17 | 9 |
| 31 Dec 18 | 22 | -12 | 17 | 9 |
| 30 Sep 18 | 21 | -22 | 17 | 10 |
| 30 Jun 18 | 49 | 6 | 16 | 10 |
| 31 Mar 18 | 51 | 10 | 16 | 13 |
| 31 Dec 17 | 37 | -1 | 16 | 13 |
| 30 Sep 17 | 36 | 7 | 15 | 13 |
| 30 Jun 17 | 9 | -18 | 15 | 15 |
| 31 Mar 17 | 8 | -16 | 15 | 13 |
| 31 Dec 16 | 7 | -16 | 15 | 14 |
| 30 Sep 16 | 8 | -14 | 15 | 16 |
| 30 Jun 16 | 10 | -16 | 15 | 15 |
| 31 Mar 16 | 47 | 16 | 16 | 17 |
| 31 Dec 15 | 48 | 14 | 17 | 15 |
| 30 Sep 15 | 49 | 21 | 19 | 15 |
| 30 Jun 15 | 47 | 18 | 21 | 13 |
| 31 Mar 15 | 5 | -34 | 13 | 22 |
| 31 Dec 14 | 8 | -38 | 25 | 12 |
| 30 Sep 14 | 5 | -51 | 16 | 17 |
| 30 Jun 14 | 9 | -52 | 28 | 7 |
| 31 Mar 14 | 5 | -44 | 18 | 16 |
| 31 Dec 13 | 6 | -43 | 25 | 13 |
| 30 Sep 13 | 4 | -43 | 20 | 20 |
| 30 Jun 13 | 3 | -44 | 20 | 24 |
Beneficios de calidad: SNT actualmente no es rentable.
Creciente margen de beneficios: SNT actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: SNT no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 30.5% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SNT en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: SNT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-10%).
Return on Equity
Alto ROE: SNT tiene un Rendimiento de los fondos propios negativo (-522.04%), ya que actualmente no es rentable.